Vaccine ETF Cathay: Updated fund product information summary and reminders of multiple risks

Vaccine ETF Guotai announced that updated fund product information summary, the fund contract will take effect on August 10, 2022, with Miaomengyu as the fund manager. The operating comprehensive fee rate is 0.77%, and the performance benchmark is the return of the CSI Vaccine and Biotechnology Index. At the same time, it discloses multiple risks, such as market, management, and liquidity risks, as well as specific risks such as deviation, volatility, and changes in the underlying index returns, as well as risks related to delisting, failed subscription and redemption of funds.